Idebenone
Noben, Raxone, Catena — a short-chain benzoquinone analog of coenzyme Q10
Idebenone (Noben, Raxone, Catena — a short-chain benzoquinone analog of coenzyme Q10) is a cognitive & mood research compound. A benzoquinone with a ten-carbon hydroxylated tail where coenzyme Q10 carries fifty carbons of isoprenoid. That single structural change is the entire pharmacological argument: the short tail makes it soluble enough to be absorbed and to move within a membrane, where Q10 taken by mouth largely does not reach mitochondria at all. Reduced to its quinol form by cytosolic NQO1, it can hand electrons to complex III and bypass a failing complex I, which is why the one place it is approved is a disease of complex I.
Idebenone quick facts
| Route | Oral |
| Frequency | 3x Daily in the approved regimen |
| Half-life | ~18 hrs terminal, but a very short plasma phase — first-pass metabolism is extensive |
| Forms | Oral |
| Evidence level | Approved in the EU for Leber hereditary optic neuropathy. Tested and not approved in Friedreich ataxia and in Alzheimer's disease. |
Read the dose before anything else. The dose that earned this molecule its one approval is 900mg a day in three divided doses; the capsules sold on the shelves that discuss it as a nootropic are 30mg. That is a thirtieth of the only regimen with a regulatory finding behind it, and the gap is not a detail because the pharmacokinetics are the problem this molecule has: first-pass metabolism is extensive and the plasma phase is short. Its record outside that one rare optic neuropathy is a long list of failed indications, which is worth knowing before treating it as a general mitochondrial supplement.
How Idebenone works
A benzoquinone with a ten-carbon hydroxylated tail where coenzyme Q10 carries fifty carbons of isoprenoid. That single structural change is the entire pharmacological argument: the short tail makes it soluble enough to be absorbed and to move within a membrane, where Q10 taken by mouth largely does not reach mitochondria at all. Reduced to its quinol form by cytosolic NQO1, it can hand electrons to complex III and bypass a failing complex I, which is why the one place it is approved is a disease of complex I.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get Idebenone
Buy Idebenone at RUPharma →The evidence for Idebenone
Graded by what exists behind each claim.
✅ Clinically validated
- Approved in the EU for Leber hereditary optic neuropathy at 900 mg/day in three divided doses. The capsules sold as a nootropic are 30 mg — a thirtieth of the only regimen with a regulatory finding behind it.
- The trial landscape in that disease is small and complicated by spontaneous recovery (Chen 2025); the long-term clinical experience reports are uncontrolled (Balta 2023); and the comparison against gene therapy is indirect because no head-to-head exists (Hassan 2025).
- Tested extensively in Friedreich ataxia and not approved for it (Jain 2022) — a second mitochondrial disease, a serious program, and it did not cross.
📊 Correlative data
- It is a short-chain analog of coenzyme Q10: a ten-carbon hydroxylated tail where Q10 carries fifty carbons of isoprenoid, which is what buys the absorption Q10 does not have (Suarez-Rivero 2021).
🧪 Theoretical / extrapolated
- Reduced by cytosolic NQO1, the quinol donates electrons to complex III and bypasses complex I — which is why its one approval is in a complex I disease.
- The mechanism argues against the retail use. A cell with a working complex I has nothing to bypass, so the predicted effect shrinks toward nothing as mitochondrial function approaches normal.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Idebenone actually does
One structural change explains the whole molecule. Coenzyme Q10 carries a benzoquinone head on an isoprenoid tail of fifty carbons. Idebenone carries the same class of head group on a hydroxylated tail of ten. That is the entire difference, and it buys two things: enough water solubility to be absorbed and distributed, and enough mobility within a membrane to move between electron carriers rather than sitting in one place Suarez-Rivero 2021.
The reduction step has a name, and it is why the molecule works where coenzyme Q10 does not. Idebenone is reduced to its quinol form in the cytosol, principally by NAD(P)H:quinone oxidoreductase 1. The quinol then donates electrons directly to complex III of the respiratory chain. The consequence is specific rather than general: it bypasses complex I. A cell whose complex I is failing can still make ATP if electrons enter downstream of the failure.
Which is exactly why its one approval is where it is. Leber hereditary optic neuropathy is caused by mutations in complex I subunits, and retinal ganglion cells are unusually dependent on that complex. The drug's indication is not a marketing choice, it is the mechanism pointed at the disease that matches it Chen 2025.
The corollary nobody selling it as a nootropic states. If the mechanism is bypassing a failed complex I, then a cell with a working complex I has nothing to bypass. The molecule's own logic predicts that its effect shrinks toward nothing as mitochondrial function approaches normal, which is the opposite of how a general cognitive enhancer would have to behave. Malik 2022 places it in the nootropic catalog; the mechanism places it in a much narrower box.
Cell, rodent, human — and where it stops
Read the dose before anything else, because the dose is the story. The regimen that earned this molecule its European approval in Leber hereditary optic neuropathy is 900 mg per day in three divided doses. The capsules sold on the shelf that discusses it as a nootropic are 30 mg. That is a thirtieth of the only regimen with a regulatory finding behind it, and the gap is not a rounding difference — it is the difference between the studied drug and something that shares its name.
What the approval rests on, stated with its limits. Chen 2025 reviews the clinical trial landscape in this disease and is candid about it: small populations, spontaneous recovery that complicates every uncontrolled series, and outcome measures that are hard to standardize. Balta 2023 is a long-term clinical experience report rather than a randomized trial. Hassan 2025 is an indirect comparison against gene therapy, which is the weakest form of comparison there is and is published because no head-to-head exists.
The record outside that one disease is a list of things that did not work. Jain 2022 is a systematic review of interventions assessed in Friedreich ataxia — a disease with a mitochondrial mechanism, in which this molecule was tested extensively, and which it is not approved for. That is the most informative fact available about its breadth: given a second mitochondrial disease and a serious trial program, it did not cross.
The transfer this page refuses. Nothing in the record above involves a healthy adult, a cognitive endpoint, or a 30 mg dose. A molecule with an orphan approval in a complex I disease at 900 mg a day is not thereby a general mitochondrial supplement, and treating it as one requires three assumptions in series that no trial has tested.
Idebenone pharmacokinetics — how much of it actually gets in
What degrades it, and it is the molecule's central problem. Idebenone undergoes extensive first-pass metabolism: the hydroxylated tail is oxidized to a carboxylic acid and the products are then conjugated by glucuronidation and sulfation before reaching the systemic circulation. Most of what is swallowed appears in plasma as conjugated metabolites rather than as free drug, which is why the approved regimen is 900 mg a day for a molecule that acts at micromolar concentrations in a dish.
The oral barrier, and the one instruction that changes exposure. It is lipophilic and poorly water-soluble, so oral bioavailability depends heavily on food; the approved product is taken with meals and the difference is not marginal. Taking a low-dose capsule on an empty stomach is a way of making an already small dose smaller.
The arithmetic that puts the 30 mg capsule in perspective. Three 300 mg doses a day is the studied regimen. A single 30 mg capsule is 3.3% of that daily total, before first-pass metabolism removes most of it. To reach the approved daily exposure from 30 mg capsules would take thirty capsules a day in three divided doses — which is not a recommendation, it is the arithmetic that shows the two products are not the same intervention.
Half-life and the comparator that does not exist. The terminal half-life is on the order of 18 hours while the free drug's plasma phase is much shorter, which is the signature of a compound whose measured tail belongs to metabolites. There is no injectable form of idebenone in clinical use, so the oral route carries the entire exposure question and there is no parenteral comparator to bound it against — unlike coenzyme Q10, where injection studies exist and show how little the oral route delivers.
What would have to be true, and how you would know it was not
Four predictions, and the first one is the honest reason to be skeptical of the retail product.
1. At 30 mg, nothing measurable will happen, and that is a prediction rather than a dismissal. The studied dose is thirty times higher and most of it is lost to first-pass metabolism. If a reader takes a 30 mg capsule and reports a clear effect, the explanation to reach for first is expectation, because the pharmacokinetics do not support the alternative.
2. CMP and GGT, baseline and twelve weeks, for anyone using it at doses approaching the studied one. A quinone cleared by hepatic conjugation at 900 mg a day is a real load on liver metabolism, and liver enzymes are the cheapest place a problem would show. Prediction: unchanged at retail doses, worth watching at clinical ones.
3. hs-CRP will not move, and naming it is the point. The mechanism is electron transfer, not anti-inflammatory signaling. A page that predicted inflammation falling would be borrowing a claim from a different molecule. If somebody's hs-CRP does fall on this drug, look for the training block, the diet change or the infection that resolved.
4. Against the product, from its own mechanism. The effect should scale with how impaired complex I is. That predicts the molecule does most in a mitochondrial disease, less in ordinary aging and least in a young healthy brain — the exact reverse of the market. It also predicts that a trial in healthy adults would be null, which is a testable statement nobody has tested.
What nobody has tested yet
Nobody has run it in healthy adults for cognition. There is no randomized trial of idebenone at any dose in cognitively normal people with a cognitive endpoint. Not a failed one — an absent one. That is the single largest gap between what this molecule is sold for and what has been measured.
Nobody has published a dose-response below the approved regimen. The trials used 900 mg a day. Whether 90 mg or 300 mg does anything at all is unknown, and it is exactly the question a buyer of 30 mg capsules needs answered.
The head-to-head against gene therapy does not exist. Hassan 2025 had to build an indirect comparison because no trial has randomized patients between the two, and indirect comparisons carry every difference between the source populations into the result.
Extrapolation, labeled as such. If the active step is NQO1 reducing the quinone, then people with the common NQO1 loss-of-function polymorphism should respond less or not at all. That is a pharmacogenomic prediction with an obvious test, a cheap genotype, and no published answer for this drug.
Idebenone — its own safety story, not its class's
Three things specific to a short-chain quinone taken by mouth.
The metabolite load is the predicted hazard, and it is dose-dependent. At the approved 900 mg a day this molecule is conjugated extensively before it reaches circulation, which puts the burden on hepatic glucuronidation and sulfation. Liver enzyme monitoring is the reasonable precaution at clinical doses and is almost certainly unnecessary at 30 mg — a distinction that only makes sense once the thirtyfold dose gap is on the page.
Discolored urine is expected and is not a warning sign. Quinone metabolites color urine reddish-brown. It is a property of the chemistry rather than a signal of harm, and it is worth stating because it is alarming the first time and is the sort of thing that sends people looking for the wrong explanation.
The people this drug is genuinely for are under specialist care. Leber hereditary optic neuropathy and Friedreich ataxia are diagnosed and managed by neurologists and ophthalmologists, and sudden painless vision loss in one eye is an emergency that needs assessment the same day rather than a supplement Chen 2025. Nothing on this page is a diagnosis, and nothing here should sit between a reader and that assessment.
Sources read for this page
- Hassan AK, Abu Serhan H. Idebenone vs. rAAV2-ND4 gene therapy in the treatment of Leber's hereditary optic neuropathy: An indirect comparison meta-analysis. Indian Journal of Ophthalmology 2025 · PMID 40272293
- Chen BS, Newman NJ. Clinical trials in Leber hereditary optic neuropathy: outcomes and opportunities. Current Opinion in Neurology 2025 · PMID 39704163
- Balta G, Cristache G, Barac AD, Anton N, Barac IR. Leber's Hereditary Optic Neuropathy (LHON): Clinical Experience and Outcomes after Long-Term Idebenone Treatment. Life (Basel) 2023 · PMID 37895381
- Jain P, Badgujar L, Spoorendonk J, Buesch K. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review. Therapeutic Advances in Rare Disease 2022 · PMID 37180421
- Suarez-Rivero JM, Pastor-Maldonado CJ, Povea-Cabello S, Alvarez-Cordoba M, Villalon-Garcia I, Munuera-Cabeza M, Suarez-Carrillo A, Talaveron-Rey M, Sanchez-Alcazar JA. Coenzyme Q10 Analogues: Benefits and Challenges for Therapeutics. Antioxidants (Basel) 2021 · PMID 33557229
- Malik M, Tlustos P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients 2022 · PMID 36014874
Idebenone — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on mitochondrial function, NAD+ availability, sirtuin signaling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
What has actually been reported
- Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Same mechanism as the prediction.
- Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay.
- There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- Active malignancy, for the survival-signaling reasoning above.
- Pregnancy — uncharacterized.
The honest unknown
- Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalog should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Idebenone — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Idebenone moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Idebenone in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Idebenone
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Idebenone — frequently asked questions
What is Idebenone?
Idebenone (Noben, Raxone, Catena — a short-chain benzoquinone analog of coenzyme Q10) is a cognitive & mood research compound. A benzoquinone with a ten-carbon hydroxylated tail where coenzyme Q10 carries fifty carbons of isoprenoid. That single structural change is the entire pharmacological argument: the short tail makes it soluble enough to be absorbed and to move within a membrane, where Q10 taken by mouth largely does not reach mitochondria at all. Reduced to its quinol form by cytosolic NQO1, it can hand electrons to complex III and bypass a failing complex I, which is why the one place it is approved is a disease of complex I.
Where can I find Idebenone dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Idebenone protocol are available to members inside Skool. This public page covers what Idebenone is, how it works and the evidence.
What is the half-life of Idebenone?
Idebenone has an approximate half-life of ~18 hrs terminal, but a very short plasma phase — first-pass metabolism is extensive, which is part of what determines how often it's dosed.
What's the evidence behind Idebenone?
Current evidence level: Approved in the EU for Leber hereditary optic neuropathy. Tested and not approved in Friedreich ataxia and in Alzheimer's disease.. Idebenone is offered for research purposes only and is not an approved medicine.
What Idebenone is used for
Idebenone appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.